Predicting Future Price Moves In Adaptimmune Therapeutics Plc ADR (ADAP)

Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) does about 1.57M shares in volume on a normal day but saw 2193208 shares change hands in Monday trading. The company now has a market cap of 296.38M USD. Its current market price is $1.16, marking a decrease of -4.92% compared to the previous close of $1.22. The 52 week high reached by this stock is $2.05 whilst the lowest price level in 52 weeks is $0.42.

Adaptimmune Therapeutics Plc ADR (ADAP) has a 20-day trading average at $0.9902 and the current price is -43.41% off the 52-week high compared with 176.19% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.0608 and its 200-day simple moving average is $0.9498. If we look at the stock’s price movements over the week, volatility stands at 10.44%, which decreases to 7.20% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 60.53 to suggest the stock is neutral.

The consensus objective for the share price is $2.79, suggesting that the stock has a potential upside of 58.42% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 30, 2024 when Scotiabank initiated the stock to “Sector Outperform” and issued a price target of $3.15. Guggenheim upgraded its price target at $5.

Adaptimmune Therapeutics Plc ADR (ADAP) stock is up 18.99% over the week and 9.43% over the past month. Its price is 46.28% year-to-date and 24.95% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.12 above consensus estimates by 0.01. The company’s next earnings report forecasts estimating quarterly EPS at -0.08 and -0.48 for whole year. Expected sales for next quarter are $8.45M, which analysts say will come at $61.98M for the current fiscal year and next year at $46.84M. In addition, estimates put the company’s current quarterly revenue at an average of $38.48M.

To reach the target analysts have set, the stock logically needs to grow 58.42 percent from here.

The company has a return on investment of -382.10% and return on equity of -302.27%. The beta has a value of 2.31. Price to book ratio is 12.16 and price to sales ratio is 16.17.